This is KidneyIntelX™

This is KidneyIntelX

Healthier kidneys made possible.

Others speak about innovation and transformation in the kidney care space. We don’t. That’s because we are not interested in innovating on today’s standard of care.

We’ve invented a new model, which uses our KidneyIntelX™ technology, and focuses on preemptive, precision-based kidney care in the early stages of disease, when it can have the most impact. Our goal: healthier kidneys and happier patients for the long-term.

Our test platform is expanding at an ambitious pace.

Today, the KidneyIntelX test platform uses our proprietary bioprognostic™ methodology to identify adult patients with type 2 diabetes and chronic kidney disease (stages 1-3b) who are at increased risk for a progressive decline in kidney function, beyond what occurs during the normal aging process. Accurately assessing patient-specific risk earlier enables clinicians to target resources, therapeutic options, and care plans more appropriately, thereby increasing the chance for slowing disease progression and improving patient outcomes.

In the future, we’ll continue our focus on kidney disease and its comorbidities by expanding our test platform to include screening, diagnosis, next generation prognostic tools, and the monitoring of efficacy and prediction of response to existing and novel therapeutics.

Diabetes is the leading cause of chronic kidney disease, representing 40%1 of its cases. That’s why kidneyintelX.dkd is focused on diabetic kidney disease.

The kidneyintelX.dkd test, which received approval from the FDA in June 2023 (Read Press Release.), will help change how we address under-recognized and undertreated progressive chronic kidney disease in adult patients with type 2 diabetes.

KidneyIntelX.dkd FDA authorization

“The progression of early-stage diabetic kidney disease (DKD) to advanced stages of disease is variable, so it is essential to identify patients who are at highest risk of advancement and as early on as possible in the disease process. Identifying the level of risk for all patients with DKD is the foundation for effective stratified care and for optimal outcomes.”

Dr Aida Vega
Associate Professor of Medicine
Director of the Mount Sinai Faculty Practice Associates Primary Care Program at Icahn School of Medicine at Mount Sinai in NY, NY

The Challenges & Unmet Need

Our Big Goals

About Our Test

How We’re Different

Proof It Works